Skip to main content
SpringerLink
Log in

Epigenomics Poised to Enter Cancer Diagnostics Market with DNA Methylation Marker Technology

  • Company Profile
  • Published:
Pharmaceutical & Diagnostic Innovation

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table 1
Table 2

References

  1. Epigenomics AG. Lehman Brothers Equity Research (2004)

    Google Scholar 

  2. Marketletter 2004; 31 (35): 24–25

  3. Roche Diagnostics and Epigenomics sign broad cancer diagnostics alliance. Available from: http://www.roche.com/med-cor-2003-03-18/ (Accessed 10 October 2004)

  4. Epigenomics presents positive results from studies using DNA methylation markers for predicting disease recurrence in breast cancer patients. Available from: http://www.epigenomics.com/en/Newsroom/Press_Releases/|2004/|; (Accessed 10 October 2004)

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Epigenomics Poised to Enter Cancer Diagnostics Market with DNA Methylation Marker Technology. Pharmaceutical & Diagnostic Innovation 2, 51–55 (2004). https://doi.org/10.1007/BF03256947

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03256947

Keywords

Search

Navigation